Issue Panel Proposal Example


(capital letters)



(must have 1 moderator; please include name, degree(s), institution, city, state, country)

Moderator: J Jaime Caro, MDCM, FRCPC, FACP, Chief Scientist, Evidera, Lexington, MA, USA and Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada


(must have 2-3 panelists from different organizations; please include name, degree(s), institution, city, state, country)

Panelists: Lars Sandman, PhD, Professor, National Centre for Priority Setting in Health-Care, Linköping University, Linköping, Sweden; Peter L. Kolominsky, MD, PhD, MBA, Professor & Director, Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen - Nürnberg, Germany, Erlangen, Germany; Alaa Hamed, MD, MPH, MBA, Head, Rare Disease, Patient Outcomes and Medical Economics, Genzyme, a Sanofi Company, Cambridge, MA, USA

Panelist Perspective

(Panelists should maintain unique perspectives in order to create a true debate. Please provide a short (50 word max) perspective for EACH panelist outlining their unique point of view regarding the Issue Panel Perspective.)

Panelist Perspective:
A successful issue panel will debate an issue and have multiple perspectives represented by the panelists. Please provide below the question which will be the subject of the debate.
(maximum 255 characters)

Issue Panel purpose

(issue to be presented)

ISSUE: Decision makers have been making strides to meaningfully incorporate the patient voice into health technology assessment (HTA). The panel will debate the role of the patient voice in HTA, and if multi-criteria decision analysis (MCDA) can facilitate this use of the patient voice. The panel reflects the diversity of perspectives on the topic. Peter Kolominsky-Rabas presents the case for a greater role for the patient voice as part of HTA, and outline ways achieve this. Lars Sandman provides a critical perspective, problematizing the role of patients in HTA and their ability to address the trade-offs required of HTA. Alaa Hamed provides an industry perspective, illustrating ongoing pilots on systematically capturing the patient voice in the rare disease space. Each panelist will speak for 10 minutes on the opportunities and challenges associated with incorporating the patient voice into HTA. This will be followed by a 15-minute panel discussion, and 15 minutes of Q&A from the audience.economic benefits and limitations of implementing novel approaches.

Issue Panel overview

(background information should be included)

OVERVIEW: Consideration of patients in healthcare decisions generally sounds like a positive aspiration, supported by reference to central ethical values like autonomy and patients’ best interest (from their own point of view). However, how to best (and the extent to which we should) consider patient perspectives in HTA is still up for debate. MCDA has been proposed as a means to involve patients in determining what factors should be considered in HTA. However, this also raises a number of challenges, including: what legitimacy and role do patient preferences have in HTA in relation to other values; how to deal with patient heterogeneity and the fact that the outcome of the HTA is associated with an alternative cost for other patient groups, which are difficult to identify; which MCDA methods are best for eliciting patients’ preferences; and how to combine patients preferences with those of other stakeholders.

Issue Panel Submissions Instructions Page | 2018 Tokyo Main Page


Contact ISPOR @ | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.